May JE, Siniard RC, Taylor LJ, Marques MB, Gangaraju R (2022) From activated partial thromboplastin time to antifactor Xa and back again. Am J Clin Pathol 157(3):321–327. https://doi.org/10.1093/ajcp/aqab135

Article  PubMed  CAS  Google Scholar 

Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK (2016) Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis 41(1):165–186. https://doi.org/10.1007/s11239-015-1315-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL (2013) Discordant aPTT and anti-xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother 47(2):151–158. https://doi.org/10.1345/aph.1R635

Article  PubMed  CAS  Google Scholar 

Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS (1998) Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 158(10):1140–1143. https://doi.org/10.1001/archinte.158.10.1140

Article  PubMed  CAS  Google Scholar 

Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, Choi HA (2016) Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther 41(5):499–502. https://doi.org/10.1111/jcpt.12415

Article  PubMed  CAS  Google Scholar 

Guervil DJ, Rosenberg AF, Winterstein AG, Harris NA, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus antifactor xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45(7–8):861–868. https://doi.org/10.1345/aph.1Q161

Article  PubMed  CAS  Google Scholar 

Whitman-Purves E, Coons JC, Miller T, DiNella JV, Althouse A, Schmidhofer M, Smith RE (2018) Performance of anti-factor xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms. Clin Appl Thromb Hemost 24(2):310–316. https://doi.org/10.1177/1076029617741363

Article  PubMed  CAS  Google Scholar 

McLaughlin K, Rimsans J, Sylvester KW, Fanikos J, Dorfman DM, Senna P, Connors JM, Goldhaber SZ (2019) Evaluation of antifactor-Xa heparin assay and activated partial thromboplastin time values in patients on therapeutic continuous infusion unfractionated heparin therapy. Clin Appl Thromb Hemost 25. https://doi.org/10.1177/1076029619876030

Gombar S, Boothroyd D, Krishnan A, Sharifi H, Hsu J, Zehnder J (2019) Increased mortality and bleeding in a large cohort of patients on heparin anticoagulation therapy with discordant anti-factor xa activity and activated partial thromboplastin time (PTT); implications for clinical management. Blood 134:712–712. https://doi.org/10.1182/blood-2019-132112

Article  Google Scholar 

Oladunjoye OO, Sleeper LA, Nair AG, Trenor CC, VanderPluym C, Kheir JN, Emani SM (2018) Partial thromboplastin time is more predictive of bleeding than anti-xa levels in heparinized pediatric patients after cardiac surgery. J Thorac Cardiovasc Surg 156(1):332–340. https://doi.org/10.1016/j.jtcvs.2018.02.101

Article  PubMed  CAS  Google Scholar 

Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, Lopes RD, Zytaruk N, Finfer S, Crowther M, Cook D (2013) Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med 39(12):2135–2143. https://doi.org/10.1007/s00134-013-3044-3

Article  PubMed  CAS  Google Scholar 

Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ (2016) Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol 1(6):682–690. https://doi.org/10.1001/jamacardio.2016.2181

Article  PubMed  PubMed Central  Google Scholar 

Subat YW, Rayes H, Hanson AC, Johnson MQ, Schulte PJ, Evans K, Weister T, Trivedi V, Gajic O, Warner MA (2020) Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. J Crit Care 58:34–40. https://doi.org/10.1016/j.jcrc.2020.04.003

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doepker B, Mount KL, Ryder LJ, Gerlach AT, Murphy CV, Philips GS (2012) Bleeding risk factors associated with argatroban therapy in the critically ill. J Thromb Thrombolysis 34(4):491–498. https://doi.org/10.1007/s11239-012-0758-y

Article  PubMed  CAS  Google Scholar 

Zhang C, Zhang Z, Mi J, Wang X, Zou Y, Chen X, Nie Z, Luo X, Gan R (2019) The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine 98(23). https://doi.org/10.1097/MD.0000000000015833

Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J (1993) Establishing a therapeutic range for heparin therapy. Ann Intern Med 119(2):104–109. https://doi.org/10.7326/0003-4819-119-2-199307150-00002

Article  PubMed  CAS  Google Scholar 

Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL (1998) College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122(9):782–798

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

Article  PubMed  CAS  Google Scholar 

Hosmer DW, Lemeshow S, Sturdivant RX (2013) Applied Logistic Regression. Wiley. https://doi.org/10.1002/9781118548387

Gorog DA, Price S, Sibbing D, Baumbach A, Capodanno D, Gigante B, Halvorsen S, Huber K, Lettino M, Leonardi S, Morais J, Rubboli A, Siller-Matula JM, Storey RF, Vranckx P, Rocca B (2021) Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J Cardiovasc Pharmacother 7(2):125–140. https://doi.org/10.1093/ehjcvp/pvaa009

Article  PubMed  Google Scholar 

Vandenbriele C, Arachchillage DJ, Frederiks P, Giustino G, Gorog DA, Gramegna M, Janssens S, Meyns B, Polzin A, Scandroglio M, Schrage B, Stone GW, Tavazzi G, Vanassche T, Vranckx P, Westermann D, Price S, Chieffo A (2022) Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock: JACC review topic of the week. J Am Coll Cardiol 79(19):1949–1962. https://doi.org/10.1016/j.jacc.2022.02.052

Article  PubMed  CAS  Google Scholar 

Aubron C, Chapalain X, Bailey M, Board J, Buhr H, Cartwright B, Dennis M, Hodgson C, Forrest P, McIlroy D, Murphy D, Murray L, Pellegrino V, Pilcher D, Sheldrake J, Tran H, Vallance S, Cooper DJ, McQuilten Z (2023) Anti-factor-xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial. Crit Care Explor 5(11):e0999. https://doi.org/10.1097/CCE.0000000000000999

Article  PubMed  PubMed Central  Google Scholar 

Adatya S, Sunny R, Fitzpatrick MJ, Colvin M, Thennapan T, John R, Dodge Zantek N, Pritzker M, Eckman P, Uriel N (2016) Coagulation factor abnormalities related to discordance between anti-factor xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices. J Heart Lung Transpl 35(11):1311–1320. https://doi.org/10.1016/j.healun.2016.09.010

Article  Google Scholar 

Rizk E, Wilson AD, Murillo MU, Putney DR (2018) Comparison of antifactor xa and activated partial thromboplastin time monitoring for heparin dosing in vascular surgery patients: a single-center retrospective study. Ther Drug Monit 40(1):151–155. https://doi.org/10.1097/FTD.0000000000000463

Article  PubMed  CAS  Google Scholar 

Swayngim R, Preslaski C, Burlew CC, Beyer J (2021) Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis. Thromb Res 208:18–25. https://doi.org/10.1016/j.thromres.2021.10.010

Article  PubMed  CAS  Google Scholar